Antibody biosimilars: Fears or opportunities?

Antibody biosimilars: Fears or opportunities?

The industrial workshop “Antibody biosimilars” was opened by Hervé Watier (CNRS UMR 7292, Université FrançoisRabelais de Tours, France), coordinator of the MAbImprove Laboratory of Excellence. He delivered his welcome address, starting with a quick recall of the LabEx MAbImprove story. This LabEx was created in 2011 and funded by “Investment for the Future” program (French “Big Loan”). He then ...

Biosimilars

Biosimilars in Rheumatology- Name Changers or Game Changers?

The first patients were enrolled in anti-TNF trials nearly 25 years ago and Remicade® and Enbrel® introduced nearly two decades ago. This was followed by a spate of other introductions and as of now 9 b io logics are approved for rheumatoid ar thr i t i s (RA) . These include anti -TNF agents (infliximab, etanercept, adalimumab, golimumab, certolizumab), IL-1 antagonist (anakinra), IL-6 antagon...

Biosimilars in Inflammatory Bowel Disease: Angels or Demons?

Submit Manuscript | http://medcraveonline.com related cost has increased consistently [3]. At the moment, there are six biological agents licensed by FDA for the treatment of CD (infliximab, adalimumab, golimumab, certolizumab, vedolizumab, and natalizumab, the last two being an anti-α4β7 and anti-α4β1integrin, respectively), and three for UC (infliximab, adalimumab, and vedolizumab), whereas t...

The fears of Navajo children: adaptation or pathology?

Past and current literature concerning the fears of children generally and Navajo children specifically is examined in the perspective of current research and in-depth interviews. The position is taken that high fear frequencies in Navajo children may not be prima facie evidence of pathology, but rather evidence of a cultural pattern that has important adaptive value. The Anglo-Saxon heritage, ...